Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Quinn›
Analysis
AddedMar 20, 2024
UpdatedJul 4, 2026
Quinn

Quinn

Pre-Seed

iollo offers an AI-guided, at-home metabolomics test that analyzes 500+ blood biomarkers to deliver personalized health and aging insights.

HQ
San Francisco, CA, US
Founded
2022
Accelerator
Y Combinator logoY CombinatorS22
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Contents

  1. 01Market Outlook
  2. 02Competitive Strengths
  3. 03Pricing Strategy
  1. 01Market Outlook
  2. 02Competitive Strengths
  3. 03Pricing Strategy

Market Outlook

The consumer health-testing market has expanded as wearables, at-home diagnostics, and personalized wellness services converge. Metabolomics is positioned to capture a share of this market by offering dynamic molecular readouts that complement genetic and microbiome tests.

iollo targets consumers interested in preventive health, biological-age tracking, and actionable lifestyle recommendations based on blood biomarkers. Longitudinal testing and AI-driven coaching are likely to be key differentiators as the market matures.

Competitive Advantages

iollo's platform measures more than 500 blood metabolites, providing a broader molecular profile than traditional clinical labs that typically test a few dozen markers. The at-home collection device is designed to stabilize the sample at room temperature, removing the need for cold-chain shipping.

The company couples mass-spectrometry analysis with machine-learning models trained on curated research to deliver personalized recommendations. Repeated testing is supported, allowing users to track biomarker trends over time rather than relying on a single snapshot.

Pricing Strategy

iollo sells its metabolomics test through tiered one-time purchase plans priced per test. The Essential plan covers five health areas starting at $299 per test. The Expanded plan, marketed as the most popular option, covers ten health areas starting at $399 per test.

The Comprehensive plan covers nineteen health areas starting at $459 per test. All plans include an AI health coach, the option to upload and analyze data from other tests, and wearable integration. The company also offers sample reports to prospective customers before purchase.